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Abstract
Background/Aim. Glimepiride, as an antidiabetic from
the group of sulfonylurea, is administered perorally in the
treatment of diabetes mellitus. The aim of this study was to
compare pharmacokinetic profiles and relative bioavailabil-
ities of the two oral formulations of glimepiride, generic and
innovator tablets, after a single dose of the active drug.
Methods. An oral dose of 6 mg glimepiride was given un-
der fasting conditions to 24 healthy volunteers. A one-week
washout period was applied between the two consecutive
periods. The serum samples obtained before dosing, and at
various time points up to 48 hours, were analyzed for gli-
mepiride concentration using the validated high-
performance liquid chromatographic method with ultravio-
let detection. Pharmacokinetic parameters representing early
(maximal concentration, time to reach maximal concentra-
tion) and total exposure (area under the curve from the time
0 to the infinite time) to glimepiride were obtained and
further analyzed using the multifactorial analysis of variance
and the non-parametric Wilcoxon signed ranks test. Com-
parison of the secondary kinetic variables was only descrip-
tive. Results. The point estimates of the ratios of geometric
means (test/reference) of maximal concentrations and areas un-
der the curve were 1.046 (90% confidence interval: 0.906−1.208)
and 1.022 (90% confidence interval: 0.856−1.220), respectively,
while the median values of times to reach maximal concentra-
tion, at 5% level of significance, did not differ significantly.
Both formulations were well tolerated. Transient mild hy-
poglycaemia, which had been noted in 6 participants, re-
solved spontaneously within 30−60 minutes. Conclusion.
Since all the parametric 90% confidence intervals for the
log-transformed main variables of glimepiride were within
the 0.80 and 1.25 interval, accepted as the definition of
bioequivalence, and the differences in times to reach maxi-
mal concentration also did not reach statistical significance,
studied tablets were considered bioequivalent.
Key words:
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Apstrakt
Uvod/Cilj. Glimepirid je antidijabetik iz grupe sulfonilureje
koji se primenjuje peroralno u lečenju dijabetes melitusa. Cilj
ispitivanja bio je da se nakon peroralnog davanja jednokratne
doze uporedi farmakokinetičko ponašanje i relativna bioras-
položivost generičkog proizvoda i referentnih tableta koje kao
aktivnu materiju sadrže glimepirid. Metode. Doza od 6 mg
glimepirida ordinirana je zdravim dobrovoljcima (n = 24) na
tašte. Pauza između dva uzastopna perioda ispitivanja iznosila
je sedam dana. Uzorci krvnog seruma prikupljeni su neposre-
dno pre davanja lekova, a posle ingestije, krv je uzimana u
prethodno definisanim vremenskim tačkama, tokom 48 sati.
Koncentracije glimepirida određivane su metodom tečne
hromatografije visoke rezolucije sa UV detekcijom. Primarni
farmakokinetički parametri, koji u potpunosti opisuju faze ra-
ne (maksimalna koncentracija, vreme postizanja maksimalne
koncentracije) i ukupne (površina ispod krive od nultog vre-
mena do beskonačnosti) izloženosti glimepiridu, statistički su
upoređeni korišćenjem analize varijanse u više pravaca i nepa-
rametrijskog Wicoxonovog testa sume rangova. Rezultati.
Kritične vrednosti za relativne razlike (ispitivani lek/referentni lek)
pojedinačnih vrednosti maksimalnih koncentracija i površina ispod
krive iznosile su 1,046 (90% interval poverenja = 0,906−1,208) i
1,022 (90% interval poverenja = 0,856−1,220). Pri nivou značajno-
sti od 5%, medijani vremena postizanja maksimalnih koncentracija
nisu se, takođe, statistički razlikovali (p = 0,8026).  Podnošlji-
vost oba farmaceutska oblika glimepirida bila je dobra. Prolaz-
na, umerena hipoglikemija, koja je zapažena kod šest ispitani-
ka, normalizovala se spontano tokom 30−60 minuta. Zaklju-
čak. Budući da su se parametarski 90% intervali poverenja za
relativne razlike logaritamski transformisanih vrednosti pri-
marnih farmakokinetičkih parametara glimepirida nalazili u ra-
sponu 0,80−1,25, što je stručno prihvaćeno kao kriterijum za
definisanje bioekvivalentnosti lekova, kao i da nije postojala
statistički značajna razlika među vremenima postizanja maksi-
malnih koncentracija glimepirida u krvi, zaključeno je da su is-
pitivani farmaceutski oblici dva proizvođača međusobno bioe-
kvivalentni.
Ključne reči:
dijabetes melitus, tip 2; lekovi, generički; sulfonilurea,
jedinjenja; terapijska ekvivalentnost; biološka
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Introduction
Glimepiride is a sulfonylurea antidiabetic. It is given
orally for the treatment of type 2 diabetes mellitus
(NIDDM). Initial oral doses of 1 to 2 mg daily may be in-
creased, if necessary, to 4 mg daily for maintenance. The
maximal recommended dose is 6 mg in the UK 
1, and 8 mg
in the USA 
2, 3.
After oral administration, glimepiride was completely
absorbed from the gastrointestinal tract. Studies with single
oral doses in normal subjects and with multiple oral doses
in NIDDM patients had shown significant absorption of
glimepiride within 1 hour after administration and peak
drug levels at 2 to 3 hours 
3. When glimepiride was given
with meals, the mean time to reach maximal concentration
[T(max)] was slightly increased and the mean C(max) and
area under the curve (AUC) were decreased less than 10%,
respectively 
3. After intravenous dosing in normal subjects,
the volume of distribution was 113 ml/kg, and the total
body clearance was 47.8 ml/min. Protein binding was
greater than 99.5% 
3, 4.
Glimepiride was completely metabolized by oxidative
biotransformation after either an intravenous or oral dose.
The major metabolites were cyclohexyl hydroxy methyl de-
rivative (M1) and carboxyl derivative (M2). Cytochrome
P450 2C9 had been shown to be involved in the biotransfor-
mation of glimepiride to M1. M1 was further metabolized to
M2 by one or several cytosolic enzymes. M1, but not M2,
possessed much lower pharmacological activity as compared
to its parent in animals 
3 and humans 
5. About 60−70% of a
dose was excreted in urine with less than 5% as unchanged
drug. M1 and M2 metabolites accounted for about 40% of
the dose. About 10 to 20% of the dose was eliminated in fe-
ces as metabolites 
3, 4, 6.
The pharmacokinetic parameters of glimepiride ob-
tained from a single-dose, crossover, dose-proportionality
study in normal subjects and from a single- and multiple-
dose, parallel, dose-proportionality studies in NIDDM pa-
tients indicated that glimepiride did not accumulate in serum,
and that its pharmacokinetics was not different 
3. The oral
clearance of glimepiride did not change over the 1-8-mg
dose range, indicating linear pharmacokinetics 
7.
Differences in gender, age, and race or obesity did not
change significantly the pharmacokinetics of glimepiride 
3, 8.
However, pathologic conditions (e.g., renal failure with cre-
atinine clearance < 20 ml/min), interactions with concur-
rently used drugs or genetic CYP polymorphism 
3, 9−12 might
affect the pharmacokinetic profile of glimepiride and thereby
contribute to the changes in therapeutic efficacy or in the ad-
verse events profile. Therapeutic failure might also occur
when a patient is switched between an innovator drug and a
non-bioequivalent generic formulation. Having in mind that
pharmacokinetic studies investigating the bioequivalence of
generic and innovator drugs could minimize such risks, the
aim of this study was to evaluate the bioequivalence of the 2
tablet formulations of glimepiride, after administration of a
single 6 mg dose of active drug. As a secondary objective,
the tolerability of both formulations was also assessed.
Methods
Study design
This was a single-dose, open-label, randomized, two-
sequence, two-period crossover pharmacokinetic study
aimed to evaluate the bioequivalence of generic glime-
piride, prepared as 6 mg tablets by the manufacturer Re-
mevita d.o.o., Niš, Serbia (Glimepirid; Test), with the
brand drug (Amaryl
® 3 mg tablets, Aventis Pharma
Deutschland GmbH, Frankfurt ab Main, Germany; Refer-
ence). Eligible volunteers were randomly assigned to one
of the two sequence groups so that, upon conclusion of
the study, each subject received both regimens. Dosing in
each of the two consecutive periods was separated by one-
week washout period.
A written informed consent was obtained from all sub-
jects prior to any study-related procedures. The study was
approved by the Drug Commission and the Ethics Commit-
tee of the Military Medical Academy, Belgrade, Serbia, on
November 22, 2005.
Prior to the clinical part of the study, the in vitro disso-
lution comparison of the test and reference drug confirmed
their pharmaceutical similarity and prompted the initiation of
the clinical pharmacokinetic trial.
Subject population
Twenty-four Caucasian subjects of both sexes (15
males, 9 females) in good physical condition, as confirmed
by the complete medical and laboratory examinations before
the study, were enrolled. The volunteers were between 20
and 50 years of age, their mean body mass was 78.1 kg and
the body mass index ranged from 20 to 26 kg/m
2. Prescrip-
tion and over-the-counter drugs, except paracetamol, were
prohibited within 14 days and 48 hours of study entry, re-
spectively.
Glimepiride dosing
Since the study was conducted as a crossover compari-
son, each subject had to receive the 2 respective oral doses of
6 mg glimepiride. Thus, after the two consecutive periods a
total exposure of each volunteer to glimepiride was 12 mg.
Under the supervision of medical staff, a single dose of
6 mg glimepiride was given with 200 ml of non-carbonated
mineral water, following an overnight fast of at least 10
hours. The dose chosen for the study was selected because it
is still below the maximal recommended dose for glimepiride
(in the USA) in NIDDM patients, and was expected to pro-
duce measurable serum levels for a sufficient portion of the
terminal elimination phase.
Blood sampling schedule
Venous blood samples (8 ml each) were collected prior
to dosing (hour 0) by direct venous puncture and at 1, 1.5, 2,
2.5, 3, 3.5, 4, 6, 9, 12, 24 and 48 hours. The samples were
allowed to clot at room temperature for 20 minutes. Within 1
hour of collection all samples were centrifuged at 3 000 rpm
for 15 minutes; the serum was then separated and frozen at
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the study (including blood taken for the 2 clinical tolerability
analyses) was approximately 300 ml.
Blood glucose content was determined regularly at time
points 0, 3, 6 and 12 hours after glimepiride ingestion or, ad-
ditionally, whenever it seemed to be appropriate due to a
suspected hypoglycaemic effect of the ingested formulation.
Assay Method
The serum samples were analyzed for glimepiride con-
centrations by high-performance liquid chromatography
combined with ultraviolet spectrometry (HPLC/UV). The
HPLC/UV set was equipped with a pump (model 2150,
LKB, Bromma, Sweden), an automatic sample system
(model AS-100, BioRad Laboratories, Inc., Hercules, CA,
USA), and a Dual λ Absorbance Detector (model 2487, Wa-
ters Corporation, Milford, MA, USA). A Clarity Lite -
2.4.0.195 software (DataApex Ltd., Prague, Czech Repub-
lic), running on a PC, was used for data acquisition and inte-
gration.
 After being refrigerated, the samples were allowed to
melt spontaneously at room temperature for 20 minutes. Ali-
quots of 1 ml of serum were dispensed into glass tubes, and 5
ml of a solution containing ethyl acetate and ether (1:1) was
added. The mixture was stirring for 15 minutes using a me-
chanical mixing extractor (model KS-50, IKA Werke GmbH
& Co.KG, Staufen, Germany), and then centrifuged at 3 000
rpm for the next 15 minutes to express the organic layer. The
aqueous phase extracts were evaporated to dryness in the
stream of air, reconstituted in a mobile phase and filtrated
through 13 mm Nylon 0.45 µm filters (Waters Corporation).
Separations were performed on a reversed-phase analytical
column (SpheriSorb S5 ODS2, 4.6 × 100 mm, particle size 5
µm; Waters Corporation), with a guard column (SpheriSorb
S5 ODS2, particle size 5 µm; Waters Corporation), at room
temperature and at the flow rate of 1.0 ml/min. The injector
loop volume was 200 µl, and the UV detector wavelength
was set at 228 nm. Mobile phase was a 50:50 mixture of
acetonitrile and phosphate buffer (pH 2.55), while the assay
was performed using an external standard. Under these con-
ditions the retention time for glimepiride was approximately
8.86 minutes. All chemicals were of HPLC and p.a. purity
and were purchased from Merck KGaA, Darmstadt, Ger-
many.
Pharmacokinetic analysis
The pharmacokinetic parameters of glimepiride were
estimated by noncompartmental calculations with Pharm
package, version 1.4 (Simed SA, Paris-Créteil, France). The
parameters were not further corrected for weight or admin-
istered dose.
The peak serum concentration [C(max)] and the time
elapsed to peak concentration [T(max)] were obtained di-
rectly from the data. The elimination rate constant [K(el)]
was obtained from the slope of the terminal log-linear phase
of the semilog plot of concentration versus time. The half-
life [T (1/2)] was calculated as ln2/K(el). The area under the
glimepiride serum concentration-time curve [AUC (0-48)]
was computed using the linear trapezoidal rule while the area
under the serum concentration-time curve from the time 0 to
the infinite time [AUC (0-inf)] was calculated as the sum of
AUC (0-48) and Ct/K(el), where t was the time of the last
measurable concentration (Ct) and K(el) was the elimination
rate constant.
The MRT (mean residence time) was defined as the ra-
tio of the area under the first moment curve [AUMC], and
AUC [MRT = AUMC/AUC]. The first moment curve was
the AUC of the product of concentration [Cp], and the time
versus time on a linear scale [Cp (t) * t].
Statistical analysis
In general, a multiplicative model was assumed for
concentration-dependent parameters, implying a logarithmic
normal distribution, whereas an additive model with the
normal distribution of non-transformed data was assumed for
the time-related parameters 
13. The pharmacokinetic pa-
rameters that describe the early and total exposure to glime-
piride, C(max), T(max), and AUC (0-inf), were derived from
the individual serum concentration-time profiles and were
subjected to statistical analysis. The comparison of the sec-
ondary kinetic parameters [AUC (0-48), K(el), T (1/2), and
MRT] was only descriptive.
After the logarithmic transformation, AUC (0-inf) and
C(max) values were subjected to the analysis of variance
(ANOVA), including the terms for subjects, treatment (se-
quence) and the time period, the residuals of which were
then tested for normality, as described by Chow and Liu 
14.
For the evaluation of bioequivalence, the point estimates and
90% confidence intervals (CIs) for the relative difference
between the test and reference formulations (test/reference)
in each subject were constructed, using the residual mean
square error obtained from the multi-factorial ANOVA. The
point estimates and the 90% CIs were then transformed back
to give the estimates of the ratio of the geometric means and
the corresponding 90% CIs for the individual ratios of the 2
formulations. A non-parametric test (Wilcoxon signed ranks
test) was performed for T(max).
Bioequivalence between the two formulations was ac-
cepted if 90% CIs transformed back for the geometric mean
ratios of AUC (0-inf) and C(max) were within the 0.80–1.25
range 
15−17, and if the differences in T(max) were not statisti-
cally significant.
Results
Dissolution test
In a phosphate buffer (pH 7.8) at 37°C (± 0.5°C), the 2
formulations under investigation dissolved at 93.3% (test)
and 94.2% (reference) within 15 minutes (USP Apparatus 2
with paddles; rotations, 75 rpm; replication, 6).
HPLC
Calibration curves (standard solution, spiked serum)
were derived from peak area ratios using a least squares re-
gression of the ratio versus the nominal concentration of
glimepiride. After the analysis of 6 triplicate samples at con-
centrations ranging from 0.005 to 0.750 µg/ml, linearity wasStrana 1018 VOJNOSANITETSKI PREGLED Volumen 63, Broj 12
Jovanović D, et al. Vojnosanit Pregl 2006; 63(12): 1015–1020.
observed in the calibration curves of glimepiride with the
correlation coefficients being both greater than 0.999.
A validated liquid chromatographic method had lower
limit of quantification (LLOQ) of 0.01 µg/ml and the limit of
detection was 0.005 µg/ml. Concentrations below LOQ were
reported as 0.0 µg/ml. The mean recovery of glimepiride ex-
traction from serum samples was 87.64% (range, 84%-90%).
For within-day and between-day analysis, the mean percent
accuracy values of quality control (QC) samples were less
than 15% of theoretical values, with precision (expressed as
relative standard deviation [RSD]) of 8.97% and 7.24% at
0.05 µg/ml of glimepiride, respectively.
Study population and tolerability
All 24 subjects, having no statistically significant dif-
ferences in baseline characteristics such as age, weight, or
heights, had completed the study, and were included in the
pharmacokinetic analysis. Six volunteers (test drug, n  =  4;
reference drug, n  =  2) reported headache, sweating and
weakness over the first 2 hours of the treatment. The corre-
sponding glycaemia was, on average, about 15% lower
(range, 7.9%−34.2%) when compared to the pre-treatment
value. Blood glucose-lowering effect gradually and sponta-
neously decreased at 30 to 60 minutes afterwards, probably
because of the homeostasis mechanism in the healthy volun-
teers.
Comparative pharmacokinetics and bioequivalence
Figure 1 shows the mean concentration-time profiles of
the 2 oral formulations of glimepiride 6 mg in serum in 24
healthy volunteers. At any of the time-points evaluated, nei-
ther the averages nor the concentrations of glimepiride dif-
fered significantly in the individual study subjects after the
administration of each of the 2 formulations. The mean
C(max) values amounted to 398.3 ng/ml (test), and 399.3
ng/ml (reference), and were attained after 3 hours. At the last
blood sampling time (48 h), serum concentrations of glime-
piride were below the LLOQ in all of the tested subjects.
The relevant pharmacokinetic parameters for the 2 for-
mulations are listed in Table 1. The residual area [difference
between AUC (0-48) and AUC (0-inf)] of glimepiride (test:
18.9%; reference: 17.8%) accounted for < 20% of the AUC
(0-48). Therefore, the stated criterion [AUC (0-48)/AUC (0-
inf) * 100% > 80%) was fulfilled, and the residual area had
no sizeable impact on the calculation of AUC (0-inf) and,
consequently, on bioavailability.
Fig. 1 − Concentration (mean ± SD) vs. time profiles of
glimepiride 6 mg in serum in 24 healthy volunteers
Neither the early exposure to glimepiride, measured as
C(max) and T(max), nor the parameters that describe its
elimination [K(el), T (1/2)] were statistically different. The
differences in MRT after the administration of the test and
reference formulations were negligible.
The results of statistical evaluation of the main pharma-
cokinetic variables of glimepiride are shown in Table 2.
Further evaluation of pharmacokinetic variables that
described the early and total exposure [AUC (0-inf)] to gli-
mepiride showed point estimates of the ratios of geometric
means of C(max) and AUC (0-inf) (glimepiride test vs. gli-
mepiride reference) to be 1.046 (90% CIs: 0.906−1.208) and
1.022 (90% CIs: 0.856−1.220), respectively. For median
T(max) values, at 5% level of significance, no significant
differences were found between the two formulations in the
study, as determined by the nonparametric Wilcoxon signed
ranks test (p = 0.8026).
Table 1
Pharmacokinetic properties of the 2 oral formulations of glimepiride (dose 6 mg)
given to 24 healthy volunteers
Test tablets Reference tablets
Parameter
Mean SD Mean SD
C(max) [ng/ml] 532.5 190.1 518.6 218.6
T(max) [h] 2.5 0.5 2.5 0.7
K(el) [L/h] 0.0894 0.0352 0.0853 0.0290
T(1/2) [h] 8.8 3.0 8.9 2.5
AUC (0-48) [ng/ml ⋅ h] 3535.2 1223.3 3346.6 1242.8
AUC (0-inf) [ng/ml ⋅ h] 4399.6 1491.8 4260.7 1330.0
MRT [h] 12.7 3.8 13.0 3.5
Mean – arithmetic mean
SD – standard deviationVolumen 63, Broj 12 VOJNOSANITETSKI PREGLED Strana 1019
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Discussion
The analysis of the assay data gathered in this study indi-
cated that the chosen HPLC/UV method was sufficiently sim-
ple, precise (RSD range 7%−9%), and accurate (CV of QC
samples,  −13.8% to +10.3%) for performing a valid bioe-
quivalence study. The lack of interference with other peaks at
the retention time of glimepiride, when blank serum samples
were tested, supported the specificity of the method. Accord-
ing to the literature 
18, 19 the sensitivity of the HPLC method
applied in this study (LLOQ, 0.01 µg/ml) was comparable to
that of HPLC methodologies used by other investigators to
determine concentrations of glimepiride. As expected, how-
ever, the HPLC method we used was less sensitive compared
with HPLC coupled to tandem mass spectrometry 
20, 21.
Twenty-four subjects were included in this study be-
cause this number arbitrarily represented a reliable sample to
assess the bioequivalence of the two products 
22, 23. A post
study calculations based on the log-ANOVA error revealed
that sample size of > 23 subjects was sufficient to show the
difference of 20% between the C(max) and AUC (0-inf) val-
ues of the test and reference products. Type I and type II er-
rors would not exceed 5 and 20%, respectively.
Intra-individual variabilities [CV-intra] of C(max) and
AUC (0-inf) for glimepiride were 30.32 and 36.95%, respec-
tively. The CV-intra value for the C(max) parameter and the
individual C(max) ranges (reference, 226−1009 ng/ml; test,
218−1034 ng/ml) obtained in the study indicated that the ab-
sorption rate of glimepiride was highly variable. The overall
pharmacokinetic profile of the test formulation of glime-
piride in the present study, however, was very similar to the
data previously published 
1−4, 24. Based on the results of this
study, C(max) and AUC (0-inf) values of glimepiride were
not significantly different, with the power (derived from
ANOVA) of 0.864 and 0.897, respectively.
Conclusion
In this small, selected population of healthy volunteers,
90% CIs for geometric means of AUC (0-inf) and C(max)
ratios were within the 0.80 to 1.25 interval proposed by the
U.S. Food and Drug Administration as the definition of
bioequivalence, and the difference between T(max) values
was not statistically significant. On that basis, considering
both early and total exposure to glimepiride 6 mg, these two
oral formulations were concluded to be bioequivalent. Both
treatments were well tolerated. Transient mild hypoglycae-
mia that had been noticed in 6 out of 24 participants was not
recognized as the unexpected or serious adverse effect of
glimepiride.
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